BridgeBio Pharma BBIO Equity Method Income
Equity Method Income at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's equity method income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's equity method income?
- BridgeBio Pharma (BBIO) reported equity method income of -$18.28M in Q1 2026.
- How has BridgeBio Pharma's equity method income changed year-over-year?
- BridgeBio Pharma's equity method income decreased by 17.5% year-over-year, from -$15.56M to -$18.28M.
- What does equity method income mean?
- The company's share of profits or losses from businesses where it holds a significant but non-controlling stake.
- How do you interpret equity method income?
- Higher income signals strong performance from strategic partners or joint ventures.
- How does equity method income compare across companies?
- Common for pharmaceutical companies engaged in collaborative R&D or co-development agreements.